JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation)
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Monkeypox Virus Infection
Conditions
Monkeypox Virus Infection
Trial Timeline
Feb 23, 2017 → Dec 31, 2025
NCT ID
NCT02977715About JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation)
JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) is a phase 3 stage product being developed by Bavarian Nordic for Monkeypox Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT02977715. Target conditions include Monkeypox Virus Infection.
What happened to similar drugs?
0 of 1 similar drugs in Monkeypox Virus Infection were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02977715 | Phase 3 | Active |
Competing Products
5 competing products in Monkeypox Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 1/2 | 33 |
| BNT166a | BioNTech | Phase 2 | 39 |
| MVA-BN | Bavarian Nordic | Phase 2 | 36 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 44 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 39 |